C Eiser1, C B Stride2, A Vora3, N Goulden4, C Mitchell5, G Buck6, M Adams7, M E M Jenney7. 1. Department of Psychology, University of Sheffield, Sheffield, United Kingdom. 2. Department of statistics, Management School, Conduit Road, University of Sheffield, Sheffield, United Kingdom. 3. Department of Paediatric Haematology, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield, United Kingdom. 4. Department of paediatric haematology, Great Ormond Street Hospital, London, United Kingdom. 5. Department of Paediatric Haematology/Oncology, John Radcliffe Hospital, Oxford, United Kingdom. 6. Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom. 7. Department of Paediatric Oncology, Children's Hospital for Wales, Heath Park, Cardiff, United Kingdom.
Abstract
BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]). METHOD: In a multi-centre prospective study, parents reported their child's generic and disease-specific HRQoL and their own care-giving burden at five time points. From 1,428 eligible patients, 874 parents completed questionnaires at least once during treatment. RESULTS: At each time point, generic HRQoL was significantly lower than equivalent norm scores for healthy children. HRQoL decreased significantly at the start of treatment, before recovering gradually (but remained below pre-treatment levels). Parents reported that older children worried more about side effects and their appearance, but showed less procedural anxiety than younger children. Concern for appearance was greater among girls than boys. Compared to Regimen B (i.e. additional doxorubicin during induction and additional cyclophosphamide and cytarabine during consolidation chemotherapy), patients receiving Regimen A had fewer problems with pain and nausea. There were no statistically significant differences in HRQoL by number of DI blocks received. INTERPRETATION: HRQoL is compromised at all stages of treatment, and is partly dependent on age. The findings increase understanding of the impact of therapy on children's HRQoL and parental care-giving burden, and will contribute to the design of future trials.
BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]). METHOD: In a multi-centre prospective study, parents reported their child's generic and disease-specific HRQoL and their own care-giving burden at five time points. From 1,428 eligible patients, 874 parents completed questionnaires at least once during treatment. RESULTS: At each time point, generic HRQoL was significantly lower than equivalent norm scores for healthy children. HRQoL decreased significantly at the start of treatment, before recovering gradually (but remained below pre-treatment levels). Parents reported that older children worried more about side effects and their appearance, but showed less procedural anxiety than younger children. Concern for appearance was greater among girls than boys. Compared to Regimen B (i.e. additional doxorubicin during induction and additional cyclophosphamide and cytarabine during consolidation chemotherapy), patients receiving Regimen A had fewer problems with pain and nausea. There were no statistically significant differences in HRQoL by number of DI blocks received. INTERPRETATION: HRQoL is compromised at all stages of treatment, and is partly dependent on age. The findings increase understanding of the impact of therapy on children's HRQoL and parental care-giving burden, and will contribute to the design of future trials.
Authors: Andrew Garas; Louise A McLean; Cinzia R De Luca; Peter Downie; Maria C McCarthy Journal: Support Care Cancer Date: 2019-03-21 Impact factor: 3.603
Authors: Gabriele Calaminus; Meriel Jenney; Lars Hjorth; Katja Baust; Mark Bernstein; Stefan Bielack; Patricia De Vos; Pancras C W Hogendoorn; Gordana Jovic; Mark Krailo; Kiana Kreitz; Neyssa Marina; Babasola O Popoola; Cristina Sauerland; Sigbjørn Smeland; Carmen Teske; Clara V Schweinitz; Jeremy Whelan; Andreas Wiener; Matthew R Sydes; Rajaram Nagarajan Journal: JMIR Res Protoc Date: 2019-09-26
Authors: Clarissa E Schilstra; Karen McCleary; Joanna E Fardell; Mark W Donoghoe; Emma McCormack; Rishi S Kotecha; Richard De Abreu Lourenco; Shanti Ramachandran; Ruelleyn Cockcroft; Rachel Conyers; Siobhan Cross; Luciano Dalla-Pozza; Peter Downie; Tamas Revesz; Michael Osborn; Frank Alvaro; Claire E Wakefield; Glenn M Marshall; Marion K Mateos; Toby N Trahair Journal: BMC Cancer Date: 2022-09-15 Impact factor: 4.638